#pharma technical development

[gyanconsulting]

The pharma technical development industry has begun to invest in digital health initiatives, with all participants exploring digital health opportunities. However, as with all “hot” topics, there is a lot of buzz surrounding digital health that can make it hard to see.

[transmutationisms]

being reductive here but i do think the covid pandemic has & continues to expose a very specific strain of techno-optimistic or utopian thinking wrt medical technologies in particular---this idea that you can simply solve a massive socio-technical problem (disease spread) through a solely technical intervention that thus requires no input or cooperation from the average person besides a vague sort of 'pro-science' stance. you see this first with the crowd who thought the 'post-vaccine world' was one in which things ought to immediately 'get back to normal' but you also see it with those who seem to believe that eg a risky recreational event (parties, bars, &c) would be magically transformed in a binary manner into a wholly 'safe' one if only people were to wear masks. in this sort of politics there is no real understanding of risk as being along a spectrum or varying according to numerous factors including people's social behaviours; instead it is a technical problem solved instantly by a singular technical intervention. there's no need then to engage in larger and messier conversations about things like capitalist de/valuation of biopower, or disabled people's right or ability to participate in society. you sidestep the whole issue because you have applied the right technical means to simply dispense with the political problem. obligatory i wear masks when i have to be in public and i am boosted and blah blah but i'm under no illusion this means i can't get or spread covid (or other diseases). but more to my point here, i think this mode of thinking has dangerous consequences for all manner of social theorising that's simply answered with a lazy appeal to technological 'development' or advance---assumed to be something we can magic away if we throw enough money at pharma companies or weapons manufacturers or whoever else. what this ultimately does is stifle political consciousness and bolster the power and epistemological authority granted to institutions tasked with producing and protecting hegemonic forms. and my point here is not 'anti-science' or techno-pessimistic either; again, i am profoundly grateful for many a technological intervention into my life and i will continue to avail myself of them, including medtech. however the fantasy that problems of political and social forms and arrangements can be solved by sufficiently advanced technology is both foolish and dangerous.

[episodicnostalgia]

Star Trek: The Next Generation, 121 (Apr. 18, 1988) - “Symbiosis”

Teleplay by: Robert Lewin, Richard Manning & Hans Beimler Story by: Robert Lewin Directed by: Win Phelps

The Breakdown

The Enterprise gang are studying a star that’s undergoing some anomalous activity, which incidentally results in technical glitches across the ship’s systems. As the crew conducts their scans, the Enterprise receives a distress signal from a small freighter that’s about to get pulled into the haywire star.  Picard & Co. are all about that rescuing lifestyle, but every attempt to that end gets thwarted by the star’s interference.  Thankfully, Tasha is able to whip up a solution using transporter-techno-babble, but the intended guests send over their cargo (instead of themselves) on the first beam- out attempt. Consequently, by the time Tasha can lock onto the actual crew she only has time to save four survivors (out of six); curiously, they don’t seem to care all that much about their fallen comrades, instead hyper-fixating on the whereabouts of their cargo. And BOY do they seem tense about it.

So what in the gosh darn heck (excuse my language) is actually going on with these folks and their zany priorities?

We quickly find out the four survivors are representatives of two neighbouring species the Ornarans (represented by T’Jon and his buddy Romas), and the Brekkians (Sobi, and his lady-friend Langor).  It’s explained that the Ornarans have been suffering for generations from a plague that is incurable.  The only treatment must be administered every few days, and can only be grown on the Brekkian home world. Since the Brekkian’s have the market effectively cornered, they can-and-do charge an exorbitant fee.  Sadly, the payment was destroyed along with the freighter, which brings us to our conflict-of-the-week. On the one hand, Sobi and Langor insist that the medicine is still theirs, since the destroyed Freighter belonged to the Ornarans (meaning technically the money never formally changed hands). Conversely, T’Jon and Romas remain adamant that the situation is not their fault, and (more to the point) that failure to deliver the medicine to their people would be catastrophic.  To make matters worse, the destroyed freighter was one of only three Ornaran ships, with the remaining two being just as susceptible to the unpredictable solar flares of their sun.

Hoping to help resolve the situation, Picard begins with two prudent steps. 1)He offers some replacement parts to upgrade the Ornarans engines, which the Brekkians would be unable to assist with even if they were willing, as they’ve never bothered to create any ships of their own (exploitation via Big Pharma is their one-and-ONLY industry, you see).  2) Picard has Dr. Crusher perform a medical inspection on the Ornarans to make sure they haven’t spread this plague to the rest o the crew.

Curiously, Crusher is unable to find any evidence of a pathogen, or even a discernable root cause for the men’s symptoms.  At the same time, Picard’s attempt to reason with the Brekkians is almost equally fruitless, except for their concession to offer two treatments for T’Jon and Romas until the matter can be resolved.  This gives Crusher the insight she needs to deduce that the Ornarans aren’t suffering from a plague at all, but rather an addiction.  It turns out the medicine actually did successfully cure the Ornarans several generations back, but it’s also highly addictive and since the withdrawal symptoms feel unbearable, the Brekkians continued the deception in order to keep making a steep profit. So naturally Picard will do the right thing, and inform the Ornarans of the truth.  Right?

…RIGHT?

Wrong!

You see the prime directive clearly states that interfering with developing/pre warp civilizations (which I guess includes the Ornarans) is strictly forbidden.  Even sharing medical research that could help the Ornarans kick their drug habit would be morally incomprehensible [on an unrelated note, I just need to take a moment to roll my eyes…  annnnddd …okay I’m good] because it would because "something something cultural contamination” or whatever.  And so it is with a heavy-but-otherwise-morally-justified-heart that Picard must step aside and allow the Brekkian oppressors to carry on with their oppressing unopposed.

BUT WAIT!  Picard has one more sneaky ace up his self-righteous sleeve.  Since he can’t won’t help the Ornarans, that means he ALSO can’t give them the engine parts for their remaining two ships.  Since that means their engines will remain susceptible to the sun’s destructive influence, the Ornarans will be unable to pick up the future shipments.  Once the psychologically devastating, and excruciatingly painful experience of withdrawal subsides (along with the near-certainty of economic collapse and a staggering death toll that will surely persist well into the foreseeable future) the Ornarans will eventually be able to kick their addiction and be freed from the Brekkian bond of corporate greed!  YAY!

Moral of the story: obeying the letter of an ostensibly well-intentioned law should unequivocally be prioritized over compassionate care, because that’s the only surefire way to achieve a utopia.

Good thing that isn’t a deeply unsettling ideology!

The Verdict

I’ve often taken issue with the Prime Directive as it stands within Star Trek canon.  In principle I can get behind the idea that the Federation has no business interfering with other civilizations and their way of life, and I can even see the merit in waiting for an alien species to become space faring (or at least capable of long-distance interstellar communication) before mucking around in their development.  My problem is with the idea that there should be any law that’s incapable of making exception for mitigating circumstances when taking into consideration the humanity (for lack of a better word) of a given situation.

After Picard sends the Ornarans and Brekkians off to their respective fates, Crusher challenges Picard’s decision not to provide aid.  Picard offers the following:

Picard: Beverly, the prime directive is not just a set of rules; it is a philosophy, and a very correct one. History has proved again and again, that whenever mankind has interfered with a less developed civilization, no matter how well intentioned that interference may be, the results are invariably disastrous.

The thing is, this is only “invariably true” because of the self-imposed internal logic used within the show. The core belief here seems to be that interference can ONLY be negative, which smacks of a colonial/settler bias.  Sure, whenever the USA and other western nations invade/interfere-with/overthrow politically corrupt nations like (for instance) Iraq or Afghanistan, it tends to go horribly wrong, but it would also be disingenuous to suggest that the US and their allies had truly-noble intentions, or even cared about the general (and largely innocent) displaced citizenry.  If Crusher had only advocated for offering weapons and ships to the Ornarans so they could invade Brekka, I would understand Picard’s refusal to provide aid.  I could even understand an argument against supplying unsupervised medical treatments, like Crusher’s alternative rehab drug, since certain pharmaceutical methods could conceivably be reverse engineered into some kind of bioweapon.  But to deny the Ornarans access to the innate truth of their imposed addiction is unconscionable, even if it does lead to a heightened conflict with the Brekkians.

Speaking of faulty internal logic, Picard’s plan is entirely dependant on the contrivance of the Brekkian’s not having any ships of their own.  There’s a scene wherein Data explains that, back in the day, the Ornarans were the more technologically advanced people until the plague shifted their focus towards being full time junkies.  Meanwhile the Brekkians, who used to be the underdogs pre-plague, have since created a paradise for themselves on backs of the Ornarans. It's suggested that the Brekkians were simply too short sighted to bother advancing any of their own technology (or even just stealing the Ornarans) for their own advantage in the meantime.  In any comparable real-world scenario, the oppressing class would almost certainly have other means at their disposal to continue their exploitative regime, which would likely continue unchallenged for quite some time.

I also can’t help but think that Picard is already playing fast-and-loose with the Prime Directive here to begin with.  Like, what exactly are the rules anyway?  In later seasons/spin-off series the Prime Directive is more-or-less defined as a policy of zero-interference for pre-warp civlizations, which seems to be the case here.  But wouldn’t that make the initial rescue attempt of the freighter a violation in itself?  You’re telling me that Picard would be forbidden from saving a pre-warp person from a housefire on the Ornaran home world, but it’s fine to save them when they’re on a space-ship even though it’s not warp-capable?  Even if you make an exception for the writers not having figured out the rules yet, it would seem Picard is still breaking the internal rules of this particular episode.

But what I find most damning of all is Picard’s unwavering dedication to the Prime Directive, especially since the writers hardly leave room for the allowance that Picard could be wrong.  Remember the opening line to Picard’s little morality speech above? 

“The prime directive is not just a set of rules; it is a philosophy, and a very correct one.”

"And a Very CORRECT one." He said, a little too self-assured.

There is no philosophy that should be exempt from revaluation and criticism.  To deny the possibility that one’s ideals could be very at least partly misguided or flawed is a very slippery slope to fanaticism.

After Picard’s proselytizing, Crusher and Picard finish their dialogue with the following:

Crusher: It’s hard to be philosophical when faced with suffering. Picard: Believe me Beverly, there was only one decision. Crusher: I Just hope it was the right one Picard: And we may never know.

That’s right Picard.  You may indeed never know.  And that should weigh more heavily on you.

1 star (out of 5)

Additional Observations

Picard IS and Asshole: I’d never watched ‘Symbiosis’ before now, so I hadn’t initially made the connection that ‘Lower Decks’ actually did a follow-up episode. [ep 309 – “Trusted Sources” in case you’re wondering] If you haven’t watched that series (which I would highly recommend) It turns out the Ornarans did indeed suffer horribly for a little over a decade before things get better, although at least they do turn it around.  We also find out the Brekkian home world would ultimately fall victim a Breen invasion that forces the survivors into hiding.  I guess one-outta-two (horrifically achieved) happy ending’s is better than none?

At one point Wesley gets judgemental about the Ornarans drug addiction because he’s too privileged to understand how anyone could be less privileged than him.  Tasha offers a speech about how beating a drug addiction is easier said than done, but even that just largely devolves into the standard ‘just say no to drugs’ rhetoric.  The sentiment would have been common enough in the late 80’s, but needless to say it’s aged poorly.

Unintentional hilarity: It’s established that the Ornarans and Brekkians possess the ability to emit an electrical charge from their hands, which can be used as a weapon.  I didn’t really talk about it before because it never has much of an impact on the story, but there’s a scene where T’Jon threatens to zap Riker dead unless Picard caters to their demands.  Picard simply calls his bluff and nothing else comes of it, but Riker’s face while he’s being “zapped frozen” cracks me up.

[transingthoseformers]

Dgixkhhxfohkfh so the accidental drunken conjunx qpr situation with Ratchet, Pharma, Soundwave, and Shockwave. The one that technically happens years in the future after the emergency of Megatron and Optimus's sparkling.

Shockwave and Soundwave have been in a firmly non romantic and not exclusive relationship for a while, sort of a "If given the choice I'd choose to frag you over anyone else here, my favorite booty call" setup. Coworkers and commanders with benefits.

Ratchet and Pharma are divorced, and will reignite a romantic and sexual relationship with each other (likely what you primarily think of when someone says the word relationship).

Ratchet and Soundwave developed an understanding as exasperated drinking buddies that complain to each other about both their respective first in commands and the silly shit that goes about in their factions.

Shockwave, Pharma, and Ratchet are mostly completely unrelated to each other, occasionally working together on science stuff and some medical stuff (i say this as Pharma canonically has demonstrated some level of inventive ability, as he created a whole complex virus even when stressed as hell. So has Ratchet, need i quote his work on Synth-en) on group projects, and know each other as their whatever's whatever.

They accidentally got married while completely shitfaced at the eventual war over party slash surprise wedding (s). On paper, they're all conjunxes, but functionally they float between conjunxes and amicas. When Influx arrives, Shockwave and Soundwave are the primary creators and Ratchet and Pharma are the beta creators (which is again what's written down on whatever Cybertronian official papers exist anymore, in reality they would all equally contribute to raising Influx and all had a say in the creation)

Essentially, a beautiful clusterfuck because this is Riot's TFP au, the nature of chaos itself.

[admissiondone321]

D-Pharma Admission 2024: Your Gateway to a Rewarding Career in Pharmacy

The healthcare industry is booming, and with it, the demand for qualified pharmacists. If you're interested in a fulfilling career in this dynamic field, pursuing a D-Pharma (Diploma in Pharmacy) could be your perfect launchpad. D-Pharma is a 2-year diploma program that equips you with the essential knowledge and skills to work as a pharmacy technician in various settings, including hospitals, clinics, community pharmacies, and pharmaceutical companies.

Why Choose D-Pharma?

Short duration: Compared to a B.Pharm degree, D-Pharma offers a quicker entry into the workforce, allowing you to start earning sooner.

Affordable: D-Pharma programs are generally more affordable than B.Pharm degrees, making them a cost-effective option for many students.

High demand: Pharmacists are in high demand across India, with the job market expected to grow significantly in the coming years.

Diverse career opportunities: D-Pharma graduates can find work in a variety of settings, from dispensing medications to conducting research and development.

Pathway to further studies: D-Pharma can serve as a stepping stone to pursuing a B.Pharm degree or other advanced pharmacy programs.

D-Pharma Admission Process 2024

The D-Pharma admission process varies depending on the college and state you're applying to. However, some general steps include:

Eligibility: Most D-Pharma programs require you to have passed your 10+2 examination with at least 50% marks in Physics, Chemistry, and Biology.

Entrance exam: Some colleges conduct their own entrance exams, while others consider scores from state-level or national-level pharmacy entrance exams like GPAT or JEE Pharmacy.

Merit-based selection: Some colleges may select candidates based solely on their 10+2 marks if they don't have an entrance exam.

Counseling and seat allocation: Based on your entrance exam score or merit, you may be called for counseling and seat allocation in colleges of your choice.

Important Dates and Links

As of today, January 24th, 2024, the specific dates for D-Pharma admission 2024 vary across states and colleges. However, some important resources you can consult include:

All India Council for Technical Education (AICTE): https://aicte-india.org/

Pharmacy Council of India (PCI): https://www.pci.nic.in/

State-level pharmacy admission portals: You can find links to these portals on the official websites of respective state governments.

Explore Your D-Pharma Journey:

For a comprehensive guide on D-Pharma admission 2024, including eligibility criteria, entrance exams, top colleges, and application procedures, visit: D-Pharma Admission 2024: https://www.admissiondone.com/d-pharma-admission-2024/.

[sudheervanguri]

Jubilant Biosys Hiring Synthesis R&D Research Associate / Senior Research Associate Embark on an exciting career journey with Jubilant Biosys Limited, a leading organization at the forefront of innovative research and discovery in the pharmaceutical industry. Currently, we have opportunities in the Synthesis Department for the roles of Research Associate and Senior Research Associate. About the Jubilant Biosys Limited Jubilant Biosys Limited is a pioneer in drug discovery and development, committed to pushing the boundaries of science to create impactful solutions for global health challenges. With a rich legacy and a forward-thinking approach, we strive to make significant contributions to the field of pharmaceuticals. Company Vacancies List Explore the dynamic vacancies available at Jubilant Biosys Limited: Position Titles: Research Associate (Synthesis Department) Senior Research Associate I (Synthesis Department) Educational Qualifications: MSc in Organic Chemistry / MPharma Experience: 02 to 8 years Location: Greater Noida/Noida Job Description Role: Synthesis R&D Research Associate / Senior Research Associate Department: R&D/Discovery Synthesis Employment Type: Full Time Role Category: Research and Development Detailed Job Description Key Responsibilities: Synthesis, purification, and characterization of novel intermediates. Deliver small to large quantities of novel chemical entities for drug discovery. Work collaboratively in a team to drive chemistry projects forward. Responsible for the safe conduct of reactions. Qualification: M.Sc in Organic Chemistry or related field / M. Pharma Experience: 4-6 years of industry experience with any leading CRO organization. Technical and Functional Skills: Excellent knowledge in basic and advanced organic chemistry. Good knowledge in functional group conversion and multiple-step synthesis. Basic knowledge of retrosynthetic analysis (desirable). Expertise in handling pyrophoric reactions. Proficiency in TLC, column purification, and extraction. Excellence in analyzing NMR, IR, and Mass Spectrometry data. Behavioral Skills: Adherence to safe laboratory practices. Enthusiasm to work in a dynamic research environment. Willingness to stretch when project challenges increase. Proficiency in computer applications (MS Word/Excel/PowerPoint) and structure drawing (Chem Draw/ISIS). Strong communication and presentation skills. Proficient in literature search using Reaxys. How to Apply Interested candidates meeting the criteria are invited to submit their resumes to v-ramneek.malhi@jubilantbiosys.com [caption id="attachment_58492" align="aligncenter" width="930"] Jubilant Biosys Recruitment Notification[/caption]

[pharma360]

Generative AI: The Future of AI-Driven Innovation

Generative AI is a groundbreaking technology that has the potential to revolutionize many industries, including healthcare, pharmaceuticals, marketing, and more. Unlike traditional AI, which focuses on analyzing and processing existing data, generative AI creates new content, from text and images to entire solutions. This innovative approach helps businesses optimize processes, streamline operations, and create new opportunities for growth. With a rising interest in generative AI, understanding its impact, benefits, and applications is essential.

What is Generative AI?

Generative AI refers to machine learning models designed to generate new data and content. These models can produce everything from written articles and artwork to technical innovations. Unlike predictive models, which analyze past data to forecast future outcomes, generative AI can create new possibilities. This advanced AI is trained on vast datasets, learning patterns, and structures, which enables it to generate outputs that mimic human creativity and decision-making.

Applications of Generative AI

Generative AI is gaining momentum in several fields, particularly in industries that require content creation, research, and product development. Some notable applications include:

Content Creation: In marketing and advertising, generative AI can create highly targeted content, including blog posts, ad copies, and social media updates. It enables companies to engage with their audiences more efficiently by automating content production.

Pharmaceutical Research: In pharma, generative AI is used to design new drugs, model biological structures, and predict patient outcomes. By rapidly generating insights from biological data, AI helps reduce the time and cost of drug development.

Product Design: Companies use generative AI in engineering and product design to create prototypes, optimize designs, and simulate real-world testing environments. This reduces time-to-market and improves product performance.

Customer Service: AI-powered chatbots and virtual assistants are another example of generative AI. These systems can engage in conversations, answer questions, and provide solutions in real time, improving customer satisfaction.

Benefits of Generative AI

The benefits of generative AI are far-reaching, making it an appealing tool across many industries. Here are some key advantages:

Increased Efficiency: Generative AI can automate time-consuming tasks, allowing employees to focus on higher-level work. In industries like pharmaceuticals and marketing, this means quicker production times and fewer manual processes.

Cost Reduction: By automating content creation, drug design, and product development, companies can significantly cut costs associated with these processes. Generative AI streamlines operations, leading to more efficient use of resources.

Personalization: In marketing, generative AI can generate tailored content for different audiences, helping businesses engage with their customers in a more personalized way. This level of customization boosts brand loyalty and customer satisfaction.

Innovation: Generative AI opens doors to new innovations by exploring combinations of ideas and creating unique solutions. Its ability to simulate and test different models encourages creative thinking and problem-solving.

Challenges and Limitations

While generative AI holds great promise, it also presents some challenges:

Quality Control: Since AI-generated content is not always perfect, businesses need to invest in proper quality control mechanisms. Ensuring the content or solutions generated by AI meet industry standards is crucial.

Ethical Concerns: Generative AI can sometimes produce content that raises ethical concerns, especially in industries like pharmaceuticals and healthcare. Ensuring that the AI’s outputs are in line with ethical standards is a significant consideration.

Data Security: With AI relying on vast amounts of data to learn and create, businesses must safeguard sensitive information. This is especially relevant in healthcare, where patient data privacy is paramount.

Bias and Fairness: Generative AI can inherit biases from the datasets it is trained on. Ensuring fairness in its outputs requires careful monitoring and diverse data inputs.

The Role of Generative AI in Pharma

Generative AI is particularly valuable in the pharmaceutical industry, where it helps optimize processes like drug discovery and development. In traditional pharma research, drug design can take years and require immense resources. Generative AI accelerates this process by analyzing biological data, modeling potential drug compounds, and simulating their effects. This not only shortens development timelines but also increases the likelihood of discovering effective treatments.

Additionally, AI-generated models can help predict patient outcomes based on genetic or environmental factors, enabling personalized medicine. As a result, treatments can be more effective, and patients may experience better outcomes.

The Future of Generative AI

The future of generative AI is promising, with ongoing advancements in machine learning and computing power. As the technology evolves, it is expected to play an even more significant role in industries like pharmaceuticals, marketing, finance, and more. With continued development, generative AI could solve complex challenges, from curing diseases to creating sustainable solutions for businesses.

Moreover, the integration of generative AI with other technologies, such as blockchain and IoT, may lead to innovative applications that further improve efficiency and security. This convergence of technologies could transform industries in ways we are only beginning to understand.

Conclusion

Generative AI is a powerful tool that is transforming industries through its ability to create new content, optimize processes, and drive innovation. In the pharmaceutical industry, it holds particular promise for drug development, personalized medicine, and research optimization. However, to fully realize the benefits of generative AI, businesses must address challenges like quality control, ethical considerations, and data security.

[jcmarchi]

3 Questions: What does innovation look like in the field of substance use disorder?

New Post has been published on https://thedigitalinsider.com/3-questions-what-does-innovation-look-like-in-the-field-of-substance-use-disorder/

3 Questions: What does innovation look like in the field of substance use disorder?

In 2020, more than 278,000 people died from substance use disorder with over 91,000 of those from overdoses. Just three years later, deaths from overdoses alone rose by over 25,000. Despite its magnitude, the substance use disorder crisis still faces fundamental challenges: a prevailing societal stigma, lack of knowledge around its origin in the brain, and the slow pace of innovation in comparison to other diseases.

Work at MIT is contributing to meaningful innovations in the field of substance use disorder, according to Hanna Adeyema MBA ’13, director of MIT Bootcamps at MIT Open Learning, and Carolina Haass-Koffler, associate professor of psychiatry and human behavior at Brown University.

Adeyema is leading an upcoming MIT Bootcamps Substance Use Disorder (SUD) Ventures program. She was the chief operating officer and co-founder of Tenacity, a startup based on research from the MIT Media Lab founded to reduce burnout for call center workers. Haass-Koffler is a translational investigator who coalesces preclinical and clinical research towards examining biobehavioral mechanisms of addiction and developing novel medications. She was a finalist for the 2023-24 MIT-Royalty Pharma Prize Competition, an award supporting female entrepreneurs in biotech and the winner of the 2024 Brown Biomedical Innovation to Impact translational commercial development program that supports innovative proof-of-concept projects. In 2023, Haass-Koffler produced a substance use disorder 101 course for the SUD Ventures program and secured non-dilutive funding from the NIH toward work in innovation in this area. Here, Adeyema and Haass-Koffler join in a discussion about the substance use disorder crisis and the future of innovation in this field.

Q: What are the major obstacles to making meaningful advances in substance use disorder research and treatment and/or innovation?

Adeyema: The complexity of the substance use disorder market and the incredible amount of knowledge required to innovate is a major obstacle to bringing research from the bench to market. Innovators must not only understand their technical domain in great detail, but also federal regulations, state regulations, and payers in the health care sector. On top of this, they must know how to pitch to specialized investors, how to sell to hospitals, and understand how to interact with vulnerable populations — often all at the same time.

Given this, solving the substance use disorder epidemic will require a multidisciplinary approach — from health care innovators to researchers to government officials and everyone in between. MIT is the right place to address innovation in the substance use disorder space because we have all of those talented people here and we know how to collaborate to solve societal problems at scale. An example of how we are working together in this way is the collaboration with the National Institutes of Health and the National Institute of Drug Abuse to create the SUD Ventures program. The goal of this program is to fuel the next generation of innovation in substance use disorder with practical applications and a pipeline to securing non-dilutive government funding from Small Business Innovation Research grants.

Haass-Kolffer: Before even mentioning substance use disorder, there are a number of barriers in health care that already exist, such as health insurance reimbursement, limited availability of resources, shortage of clinicians, and more. Specifically in substance use disorder, there are additional barriers affecting patients, clinicians, and innovators. Barriers on the clinical side include, but are not limited to, lack of resources available to providers and lack of time for physicians to include additional substance use disorder assessments in the few minutes that they spend with a patient during a clinical visit. Then on the patient side, the population is often composed of individuals from low socio-economic groups, which adds issues related to stigma, confidentiality and lack of referral network, and generally hinder development of novel substance use disorder treatment interventions. 

At a high level, we lack the integration of substance use disorder prevention, diagnostic, and treatment in health care settings. Without a more holistic integration, advancing substance use disorder research and innovation will continue to be extremely challenging. By creating a collaborative program where we can connect researchers, clinicians, and engineers, we have the opportunity to bring together a dynamic community of peers to tackle the biggest challenges in providing treatment of this debilitating disorder.

Q: How does the SUD Ventures program approach substance use disorder innovation differently?

Adeyema: Traditionally, innovation programs in the substance use disorder space focus on entrepreneurship and business courses for researchers and inventors. These courses focus on knowledge, rather than skills and practical application, and omit an important piece of building a business — it takes an entire ecosystem to build a successful startup, particularly in the health care space.

Our program will bring together the top U.S.-based substance use disorder researchers and experts in other disciplines. We hope to tap into MIT’s engineering excellence, clinical expertise from places like Massachusetts General Hospital, and other academic institutions like Harvard University and Brown University, which is a major center for substance use disorder research. With the vibrant entrepreneurship and biomedical expertise in the Boston ecosystem, we are excited to see how we can bring these incredible forces together. Participants will work together in teams to develop solutions in specific topic areas in substance use disorder. They are guided by MIT-trained entrepreneurs who have successfully funded and scaled companies in the health care space, and have access to a strong group of mentors like Nathaniel Sims, associate professor of anesthesia at Harvard Medical School and the Newbower/Eitan MGH Endowed Chair in Biomedical Technology Innovation at Massachusetts General Hospital.

We recognize the field has many idiosyncratic challenges, and it is also changing very, very fast. To shed light on the most recent and unique roadblocks, the SUD Ventures program will rely on industry case studies delivered by practitioners. These cases will be updated each year to contribute to a body of knowledge participants have access to not only during the program, but also after.

Q: Looking forward, what is the future of innovation in the substance use disorder field, and what are the promising innovations/therapies on the horizon?

Haass-Koffler: The opportunities to develop technologies to treat substance use disorder are infinite. Historically, the approach has been centered on neurobiology, focusing predominantly on the brain. However, substance use disorder is a complex disorder and lacks measurable biomarkers, which complicates its diagnosis and management. Given the brain’s connections with other bodily systems, targeting interventions beyond the central nervous system offers a promising avenue for more effective treatment.

To improve the efficiency of treatment by both researchers and clinicians, we need technological advancements that can probe brain function and monitor treatment responses with greater precision. Innovations in this area could lead to more tailored therapeutic approaches, enable earlier diagnosis, and improve overall patient care.

Just as glucose monitoring changed lives by managing insulin delivery in diabetes, there is a significant opportunity to create similar tools for monitoring medication responses, drug cravings, and preventing adverse events in patients with substance use disorder, affecting their lives tremendously. The future for the substance use disorder crisis is two-fold: it’s about saving lives by preventing overdoses today and improving quality of life by supporting patients throughout their extended treatment journeys. We are innovating and improving on both fronts of the crisis, and I am optimistic about the progress we will continue to make in treating this disease in the next couple of years. With government and political support, we are improving people’s lives and improving society.

The program and its research are supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH). Cynthia Breazeal, a professor of media arts and sciences at the MIT Media Lab and dean for digital learning at MIT Open Learning, serves as the principal investigator (PI) on the grant.

[agnivesh09]

The Benefits of Pharma Consulting Services for Small and Mid-Sized Pharmaceutical Companies

In the dynamic and highly regulated pharmaceutical industry, small and mid-sized companies face a myriad of challenges that can impede their growth and operational efficiency. From navigating complex regulatory landscapes to optimizing product development and enhancing market access, these challenges can be overwhelming. This is where pharma consulting services become invaluable, offering tailored expertise that can drive significant improvements in various aspects of business operations. Here’s an exploration of the key benefits that pharma consulting services offer to small and mid-sized pharmaceutical companies.

1. Navigating Regulatory Compliance

Regulatory compliance gap analysis is one of the most significant challenges faced by pharmaceutical companies. With regulations that vary widely across different regions and are constantly evolving, maintaining compliance requires deep expertise. Pharma consultants specialize in regulatory affairs services  and can guide companies through the process of regulatory submissions, ensuring compliance with all local, regional, and international laws. This not only helps in avoiding costly legal issues but also speeds up the time to market for new products.

2. Streamlining Product Development

Product development in the pharmaceutical sector is a costly and time-consuming process. Pharma consultants bring on board their technical expertise to streamline product development strategies. They assist in implementing efficient protocols for clinical trials application, help in designing and conducting experiments, and provide insights into enhancing the formulation of pharmaceutical products. This optimization leads to a reduction in time and cost overruns, ensuring that products reach the market faster and are developed within budget.

3. Enhancing Market Access and Commercialization

Understanding the market dynamics and successfully launching a product are crucial for the survival of small and mid-sized pharma companies. Pharma consultants offer strategic market analysis that helps these companies identify the right markets for their products. They assist in developing effective market entry strategies and in crafting value propositions that resonate with stakeholders like healthcare providers, payers, and patients. Furthermore, consultants can aid in negotiating with distributors and setting up sales channels, significantly improving market penetration.

4. Focusing on Patient-Centric Approaches

In today’s healthcare environment, focusing on patient outcomes is vital for gaining a competitive edge. Pharma consultants help companies adopt patient-centric models that emphasize improved patient outcomes and personalized medicine. They can guide the integration of patient feedback into the product development process, ensuring that the end products align well with patient needs and expectations, thereby enhancing patient satisfaction and loyalty.

5. Facilitating Strategic Partnerships and Collaborations

For small and mid-sized firms, forming strategic partnerships can be a gateway to new technologies, expanded markets, and additional resources. Pharma consultants can identify potential partners, facilitate negotiations, and help manage these relationships. Whether it’s outsourcing certain R&D processes or collaborating on marketing efforts, these partnerships can provide essential support that allows smaller companies to scale effectively without bearing all the costs alone.

6. Implementing Cost-Control Measures

Cost management is crucial for maintaining profitability in the competitive pharmaceutical industry. Consultants can provide critical insights into areas where companies can reduce costs without compromising on quality. This might include optimizing supply chain operations, improving manufacturing processes, or reducing waste through better inventory management. Effective cost-control strategies ensure that companies remain financially healthy and can invest in future growth.

7. Advancing Technological Integration

In an era dominated by technological advancements, staying updated with the latest technologies is crucial. Pharma consultants help integrate new technologies into existing systems, such as adopting artificial intelligence for drug discovery or implementing advanced data analytics for market research. This technological empowerment enables companies to stay ahead of the curve, improve efficiencies, and offer innovative solutions that meet contemporary needs.

8. Providing Training and Support

Pharma consultants do not just offer advice and then step away; they also provide ongoing training and support to ensure that the pharmaceutical company’s staff can sustain improvements over the long term. This includes training on new technologies, regulatory compliance in  pharmaceuticals industry, and best practices in pharmaceutical management. Such educational initiatives empower employees and foster a culture of continuous improvement.

Conclusion

For small and mid-sized pharmaceutical companies, the complex challenges of the industry necessitate specialized expertise that pharma consulting services are uniquely positioned to provide. From regulatory navigation and product development to strategic market entry and cost management, consultants offer a range of services that can catalyze growth and ensure sustainability. Engaging with a pharmaceutical consultant could very well be the catalyst that transforms challenges into opportunities for lasting success.

Our other services:-

Medical device services

Regulatory Software

Pharmacovigilance Consulting Services

[krigenicagripharma]

Krigenic Agri Pharma: Leading the Way in Agricultural Excellence in India

Krigenic Agri Pharma is a distinguished name in the Indian agricultural landscape, known for its comprehensive range of high-quality products and services tailored to the needs of modern farming. Our mission is to empower farmers with the tools and knowledge necessary to achieve high productivity while embracing sustainable farming practices. We understand the challenges faced by today’s farmers and strive to provide innovative, effective solutions that drive success and profitability.

Our Expertise:

Crop Protection:

Our extensive range of crop protection products, including herbicides, fungicides, and insecticides, helps safeguard crops from pests, diseases, and weeds.

We prioritize the development of environmentally responsible solutions that protect crops without compromising soil health or biodiversity.

Soil Management:

Healthy soil is the foundation of successful farming, and our soil management products are designed to improve soil structure, fertility, and overall health.

We offer a variety of soil conditioners, organic amendments, and micronutrient solutions that cater to the specific needs of different soil types and crops.

Fertility Enhancement:

Boosting soil fertility is essential for maximizing crop yields. Our range includes both organic and inorganic fertilizers, water-soluble fertilizers, and seed treatment solutions that ensure optimal nutrient availability and uptake.

Our products are formulated to enhance the efficiency of nutrient use, thereby reducing waste and environmental impact.

Commitment to Innovation:

Research and Development:

At Krigenic Agri Pharma, innovation is at the heart of our operations. We invest significantly in R&D to develop cutting-edge products that address the evolving challenges of agriculture.

Our commitment to innovation ensures that farmers have access to the latest advancements in crop protection, soil health, and fertility enhancement.

Sustainability and Environmental Responsibility:

We are dedicated to promoting sustainable farming practices that balance productivity with environmental stewardship. Our products are designed to minimize ecological impact while maximizing agricultural output.

From integrated pest management strategies to sustainable nutrient management practices, we offer solutions that help farmers reduce their carbon footprint and preserve natural resources.

Farmer Support and Services:

Expert Guidance:

Beyond products, we provide farmers with expert guidance and technical support to help them make informed decisions. Our agronomic advisory services include soil testing, crop planning, and customized recommendations tailored to specific farming needs.

Empowerment Through Knowledge:

We believe in empowering farmers through education and training. Our capacity-building programs and knowledge-sharing initiatives equip farmers with the skills and resources needed to adopt modern agricultural practices and improve their livelihoods.

Discover the Krigenic Agri Pharma Difference:

With a focus on quality, innovation, and sustainability, Krigenic Agri Pharma is committed to helping farmers achieve higher productivity and profitability. Our broad portfolio of agricultural products and services is designed to meet the diverse needs of India’s farming community.

Explore our full range of solutions and discover how Krigenic Agri Pharma can support your agricultural operations by visiting www.krigenicagripharma.com or calling 9900937013. Partner with us for a future of enhanced productivity, sustainable farming, and agricultural excellence in India.

[gyanconsulting]

The pharma technical development industry has begun to invest in digital health initiatives, with all participants exploring digital health opportunities

[cosmenova]

What Support Can You Expect from a PCD Pharma Franchise Provider?

Choosing a PCD Pharma Franchise is a significant decision for entrepreneurs looking to enter the pharmaceutical industry. Partnering with a reputable PCD Pharma Franchise provider can offer numerous benefits and support to ensure your business’s success. Here’s what you can typically expect in terms of support from a Derma PCD Pharma Franchise provider like Cosmenova.

1. Product Range and Quality Assurance

Diverse Product Portfolio: A reliable PCD Pharma Franchise provider offers a comprehensive range of high-quality pharmaceutical products. This includes both prescription and over-the-counter medications across various therapeutic segments.

Quality Control: You can expect stringent quality checks and compliance with regulatory standards. Providers like Cosmenova ensure that their products meet the highest quality standards, providing assurance to you and your customers.

2. Marketing and Promotional Support

Promotional Materials: Expect to receive a variety of marketing materials, including brochures, visual aids, and product samples. These tools are designed to help you effectively promote and sell the products.

Branding Assistance: Many franchise providers assist with branding and promotional strategies, helping you build a strong market presence and enhance your brand image.

3. Training and Guidance

Product Training: Comprehensive training programs are provided to educate you and your team about the products, their benefits, and how to market them effectively.

Sales Training: Learn effective sales techniques and strategies to boost your franchise’s performance and achieve better results.

4. Distribution and Logistics Support

Efficient Supply Chain: A reliable provider ensures a smooth and efficient supply chain, including timely delivery of products to your location.

Inventory Management: Support with inventory management helps you maintain optimal stock levels, reducing the risk of shortages or overstocking.

5. Regulatory and Legal Assistance

Compliance Guidance: Assistance with regulatory requirements and compliance helps ensure that your business operates within legal frameworks, avoiding potential legal issues.

Documentation Support: Help with necessary documentation and approvals required for marketing and selling pharmaceutical products.

6. Business Development and Networking

Market Insights: Access to market research and insights helps you understand industry trends and make informed business decisions.

Networking Opportunities: Opportunities to connect with other franchisees and industry professionals for shared learning and growth.

7. Technical and After-Sales Support

Technical Assistance: Support with any technical issues related to the products or marketing processes.

Customer Service: Ongoing customer support to address any queries or concerns you may have, ensuring smooth operations.

8. Financial and Promotional Incentives

Incentive Programs: Many franchise providers offer attractive incentive programs, including discounts, rebates, or performance-based rewards.

Flexible Terms: Negotiable terms and conditions to help align with your financial capabilities and business goals.

Partnering with a PCD Pharma Franchise provider like Cosmenova means gaining access to a comprehensive support system designed to foster your success. From high-quality products to marketing assistance and regulatory support, the right provider can make a significant difference in your business’s growth and profitability.

[forblogmostly]

Sudarshan Pharma Expands Horizons with the Incorporation of Subsidiary 'Sudarshan Maven Pharma Pvt. Ltd.'

In an important strategic development, Sudarshan Pharma Industries Ltd., a prominent player in the pharmaceutical and chemical sectors, has announced the incorporation of its new subsidiary, Sudarshan Maven Pharma Pvt. Ltd. This move marks a significant milestone in the company’s journey toward expanding its footprint in the pharmaceutical industry, particularly in the specialized segments of API (Active Pharmaceutical Ingredients) and intermediates.

On August 28, 2024, the company's board shared the news of the new subsidiary’s incorporation with the Bombay Stock Exchange (BSE). The Certificate of Incorporation, dated August 27, 2024, was issued by the Registrar of Companies, marking the official birth of Sudarshan Maven Pharma Pvt. Ltd. As a testament to Sudarshan Pharma Industries Ltd.'s commitment to growth and diversification, the parent company has subscribed to 7,000 equity shares of ₹10 each, thereby holding a 70% stake in the newly established subsidiary.

The creation of Sudarshan Maven Pharma Pvt. Ltd. is not just an expansion; it represents a strategic alignment with Sudarshan Pharma Industries Ltd.'s broader vision to cement its position in the global pharmaceutical market. The newly formed subsidiary will focus on the manufacture, formulation, and development of a wide array of pharmaceutical products, including APIs, intermediates, antibiotics, and other specialized chemical compounds. In addition, Sudarshan Maven Pharma Pvt. Ltd. will delve into the production of healthcare products, nutraceuticals, dietary supplements, and Ayurvedic preparations, catering to the diverse needs of the global healthcare market.

This new venture is expected to enhance Sudarshan Pharma's capabilities in delivering high-quality, innovative solutions in the pharmaceutical domain. The company aims to leverage its expertise in chemical and pharmaceutical manufacturing to create a robust portfolio of products that will serve not only the domestic market but also have a significant impact on the global stage. The incorporation of Sudarshan Maven Pharma Pvt. Ltd. is a clear indication of Sudarshan Pharma Industries Ltd.'s intent to diversify and strengthen its business verticals, particularly in areas that promise growth and innovation.

As part of its strategic vision, Sudarshan Maven Pharma Pvt. Ltd. will also engage in the import and export of pharmaceutical products, thereby enhancing its global reach and operational capabilities. The subsidiary's business model includes the manufacture and processing of medicinal preparations, vaccines, and various chemical products, positioning it as a comprehensive player in the pharmaceutical and healthcare sectors.

Furthermore, the new subsidiary will carry forward Sudarshan Pharma Industries Ltd.'s legacy of innovation by undertaking research and development activities, conducting clinical trials, and engaging in scientific and technical investigations. This approach will not only bolster the company’s product offerings but also pave the way for future advancements in the pharmaceutical industry.

The incorporation of Sudarshan Maven Pharma Pvt. Ltd. aligns with Sudarshan Pharma Industries Ltd.'s ongoing efforts to expand its market presence and enhance its product portfolio. The subsidiary's focus on developing high-quality pharmaceutical products, coupled with its commitment to innovation, is expected to drive significant growth for the company in the coming years.

This strategic move also reflects the company's dedication to meeting the evolving needs of the pharmaceutical industry and its customers. By establishing Sudarshan Maven Pharma Pvt. Ltd., Sudarshan Pharma Industries Ltd. is positioning itself to better serve the global market with cutting-edge products and solutions that address the growing demand for high-quality pharmaceuticals and healthcare products.

As Sudarshan Pharma Industries Ltd. continues to evolve and expand its operations, the incorporation of Sudarshan Maven Pharma Pvt. Ltd. marks a new chapter in the company’s history. With a strong foundation and a clear vision for the future, Sudarshan Pharma is poised to make significant strides in the pharmaceutical industry, both in India and globally.

The announcement of the new subsidiary was made with the expectation that it will play a crucial role in the company’s growth strategy. Sudarshan Pharma Industries Ltd. remains committed to its mission of providing innovative, high-quality products that contribute to the betterment of society, and the incorporation of Sudarshan Maven Pharma Pvt. Ltd. is a key step in fulfilling that mission.

As the subsidiary begins its operations, all eyes will be on Sudarshan Maven Pharma Pvt. Ltd. to see how it will contribute to the parent company’s legacy of excellence and innovation in the pharmaceutical and healthcare industries. With this new venture, Sudarshan Pharma Industries Ltd. is set to reinforce its position as a leader in the industry, driving growth and delivering value to its stakeholders.

[timbrehealthcare]

Best Pharma Franchise Company in Kerala

Timbre Healthcare is a fast-growing pharma franchise company that has supplied health products in this industry for a very long period of time. We have a vast network across India supplying various pharmaceutical products to government, semi-government and other institutional organisations. We deal in PCD and Third party manufacturing services. That is why we are the Best PCD pharma franchise in Kerala. The company strength lies in its technical background, Market knowledge and a quality strong fundamental team with a strong vision.

We have made ourselves the best franchise Company in India. Our aim is to give a healthy life to all the individuals. When starting a business in the industry through the franchise route, choosing the right partner plays a very important role in the pharma industry.

What is a Franchise model?

A franchise business is a model where you get the authority to run business operations on behalf of a pharmaceutical company. The franchise manages the complete product cycle, from manufacturing to marketing.

For more information, click here:

Basic needs you see while choosing Pharmaceutical franchise:

Well, there are many boxes to tick before choosing a suitable partner, but here are some boxes that a young entrepreneur should check :

1 Quality of the product:- Make sure that the quality of the product is very good because if not, then it will lose your customers as well as profit.

2 Transparency:- Try to build a good and healthy relationship with the manufacturer that helps you and the manufacturer to share each and every problem and find a solution.

3 Track record:- Do your proper research and check the previous record of the company that helps you find your best manufacturing company.

Why are we the best?

Product range:

In the Pharma business, the wide range of products matters to grow the business. At Timbre Healthcare, we have a vast range of products that help our partner expand their business and earn more profit. Whether it's generic medicines, herbal remedies, or another diet supplement, we believe that every product is handled with care and delivered safely.

Research team:

In the Pharma industry, we are always looking for new technologies. At Timbre, we have a professional research and development team (R&D) team that is always trying new formulations, technologies, and drug delivery systems. Also, focusing on R&D allows us to develop high-quality products that the market needs.

Quality Assurance:

At Timbre, we never compromise on our product quality. We monitor our product from manufacturing it from material to its end product. Our quality team checks all the product parameters, and then it is ready to ship.

IN THE END:

In this business, choosing the right manufacturer is difficult, but it is not anymore because Timbre Healthcare ranks among the We are Best PCD pharma franchise in India. are committed to growing your business with our commitment, customer service, and transparency. So don’t waste your time and grow your business with us.

FAQ’s

1. What is a PCD Pharma Franchise?

A PCD Pharma Franchise is a business model where a pharmaceutical company (franchisor) grants the rights to an individual or a company (franchisee) to promote and sell its products in a specific geographic area. This model allows franchisees to leverage the established brand and products of the franchisor.

2. What is the initial investment required for a Timbre Health Care PCD Pharma Franchise?

The initial investment varies based on the location and scale of operations but typically includes the cost of stock, infrastructure, and marketing. Timbre Health Care will provide detailed information during the application process.

[sudheervanguri]

Wipro is currently seeking skilled professionals with 4-6 years of experience in medical writing for their growing team. This opportunity is perfect for those with expertise in Clinical Evaluation Reports (CER), Periodic Safety Update Reports (PSUR), and Post Market Clinical Follow-Up (PMCF). With a flexible hybrid work model available, this position is open to candidates across Pan India. Job Overview: Company: Wipro Ltd. Position: Medical Writers | CER, PSUR, PMCF | Medical Devices Work Location: Pan India (Hybrid) Experience Required: 4-6 years Qualification: Life Science Graduate Job Type: Full-time, Mid-Senior Level Key Responsibilities: CER Writing and Drafting: PSUR Development and Updates PMCF Planning and Reporting Cross-functional Collaboration Qualifications and Requirements: Educational Background: A Life Science Graduate is required. Preferred degrees include B.Sc., M.Sc., B. Pharma, M. Pharma or other relevant qualifications related to the medical field. Professional Experience: 4-6 years of experience in medical writing, particularly in the medical devices industry. Experience working on Clinical Evaluation Reports (CER), PSUR, and PMCF is a must. Technical Skills: Proficiency in medical writing tools and understanding of ISO 13485, MDR, and regulatory guidelines. Strong research and analytical skills to interpret clinical data and present findings clearly. Soft Skills: Excellent written and verbal communication skills. Ability to work collaboratively in a cross-functional team environment. How to Apply: Interested candidates are applying through LinkedIn

[aventurahealthcare92]

Best quality pcd pharma franchise company in india

Given the great need for healthcare products and services, the Indian pharmaceutical company has expanded greatly, and the medical franchise looks profitable in 2024. Starting a pharmacy franchise is one very profitable business prospect.  Aventura Healthcare is the best quality pharma franchise company in India. The pharma franchise model presents a possible path of investment in the growing industry. Franchisees have operational freedom and can grow their companies in line with market demand. 

What do you understand about the PCD pharma franchise? 

In the pharmaceutical sector, a pharma franchise is a business structure whereby a franchisee markets and distributes the goods of a pharmaceutical company under its brand name in a specified geographical area. Propaganda Cum Distribution, or PCD,

Here are some key features of the PCD Pharma Franchise:

1. small geographic area:

The franchisee is given sole authority to promote and distribute franchisor items within a designated geographical area.

2. Little expenditure:

Compared to launching an independent pharma company, the PCD Pharma Franchise business model calls for a small investment. This is so since the franchisee does not have to make investments in production, research, development, or product registration.

3. Marketing assistance:

The franchisor offers the franchisee constant assistance, training, and marketing tools, including promotional materials.

4. High profitability potential:

The cheap overheads and strong margins on pharmaceutical products under the PCD Pharma Franchise business model suggest great profitability. Elkos Healthcare offers monopoly basis best PCD pharma franchise products.

5. availability of high-quality goods:

The franchisee gains access to premium goods previously produced, tested, and certified by regulatory agencies. Elkos supplies WHO-GMP Certified PCD Pharma Products.

6. Compliance with rules: regulatory

Ensuring that the items satisfy all legal criteria—including manufacture, packaging, labeling, and distribution—falls to the franchisor.

7. flexibility:

The franchisee can set their working hours and run the company out of a modest rented location or from a home office.

Factors Increasing the PCD Pharma Franchise Development

Recurring Business: 

Retail franchises of pharmacies often carry items like over-the-counter and prescription medications that their customers routinely need. This might lead to a lot of returning business, thereby providing the franchise with a consistent source of cash.

Technological development:

Many technical developments have allowed the pharmaceutical industry to grow more easily—the application of technology, including consultations and medication delivery, via websites. Healthcare product’s reach and accessibility have grown as so.

Product Quality: 

In an industry where effectiveness and safety rule first, the quality of a product can be quite important in building the confidence of a customer. Ensuring that your product range satisfies all legal criteria for outstanding quality is really vital. Crucially important are research and testing on product quality.

Support for marketing and sales:

The help of the parent firm in sales and marketing adds another vital element to success. This covers keeping constant contact with franchisees, training, and distribution of promotional items.

Relationships with Consumers:

Close ties with customers and healthcare professionals help the pharmaceutical sector somewhat fulfill its goals. It is verifying that the parent company provides client assistance via easily available channels of contact, etc. This could build customer trust and loyalty as well as preserve them.

In Bottom line 

PCD Pharma Franchise presents a profitable business prospect for anyone seeking a low-risk, high-profit pharmaceutical sector venture. To make sure the franchise agreement is fair and advantageous, however, it is advisable to investigate the franchisor and its products and speak with legal and financial professionals before making a franchise investment.  Aventura Healthcare Private Limited is the best quality pharma franchise company in India.  The company emphasizes giving its customers committed customer service together with top quality, reasonably cost products. Aventura Healthcare operates throughout pan India.  Here concludes your search for PCD Pharma Franchise companies.